Opioid abuse and addiction (e.g., heroin, OxyContin) remains a critical national public health concern.In 2002, tabletformulations of the medication Buprenorphine were approved by the Food and Drug Administration for the treatment of opioid addiction. In order to prepare the field to effectively integrated this new treatment, the Buprenorphine Treatment Blending Team developed an awareness training to disseminate information and enhance awareness among multidisciplinary (non-physician) addiction professionals about Buprenorphine treatment. This training is designed to provide a broad overview of the medication, its effects, and the role of non-physician practitioners in providing and supporting the treatment of individuals receiving this medication.
To obtain an overview of the Buprenorphine Treatment Blending product, download the brochure.
Blending Product Materials (download now!)
"This is a well thought-out training program, well-designed
& well-presented. As a counselor in a treatment program
which uses buprenorphine regularly, I learned a great deal
about what we're doing, and picked up suggestions to improve
the delivery of our services."
- Roger Ogren, MS, LAC
Buprenorphine Treatment Blending Team Members
Thomas Freese, Ph.D. – Pacific Southwest ATTC (Chair)
Glenda Clare, M.A. – Central East ATTC
Beth Rutkowski, M.P.H. – Pacific Southwest ATTC
Gail Dixon, M.A. - Southern Coast ATTC